Skip to main content


Browse the latest news, expert commentary, and educational content on vasculitis.

Hand in blue glove holding samples for DNA amplification with orange reaction mictures

07-11-2022 | Giant cell arteritis | News

Studies evaluate medications, biomarkers linked to GCA risk

Findings from two studies published in Rheumatology suggest that angiotensin receptor blocker use may be associated with an increased risk for developing giant cell arteritis, and that interferon-γ may warrant further investigation as a risk biomarker.

Monoclonal antibody concept

22-09-2022 | Polymyalgia rheumatica | News

SEMAPHORE: Tocilizumab reduces disease activity in steroid-dependent polymyalgia rheumatica

The IL-6 receptor inhibitor tocilizumab may significantly reduce disease activity and the amount of prednisone needed in people with glucocorticoid-dependent active polymyalgia rheumatica, suggest results from a phase 3 trial published in JAMA.

05-09-2022 | ANCA-associated vasculitis | News

Cytomegalovirus infection may be a VTE risk factor in ANCA-associated vasculitis

Results from a retrospective analysis suggest that cytomegalovirus seropositivity at ANCA-associated vasculitis diagnosis is an independent risk factor for developing venous thromboembolism.

02-08-2022 | Granulomatosis with polyangiitis | News | Article

Sequential rituximab, mepolizumab regimen may warrant further investigation for EGPA

Sequential treatment with rituximab followed by mepolizumab may be a promising strategy to treat the systemic and respiratory manifestations of eosinophilic granulomatosis with polyangiitis, suggest findings from an observational study.

21-07-2022 | Granulomatosis with polyangiitis | News

VTE may be ‘recurrent comorbidity’ in granulomatosis with polyangiitis

Recurrent venous thromboembolism is more common in people with granulomatosis with polyangiitis than among individuals in the general population who had an unprovoked first event, US researchers report in Rheumatology Advances in Practice.

04-06-2022 | EULAR 2022 | Conference coverage | News

Sarilumab shows treatment promise in relapsing polymyalgia rheumatica

Phase 3 SAPHYR study findings suggest that the IL-6 receptor inhibitor sarilumab with glucocorticoid taper is an efficacious treatment option for patients with steroid-resistant polymyalgia rheumatica.

02-06-2022 | EULAR 2022 | Conference coverage | News

Mortality risk may be ‘slightly increased’ in women with polymyalgia rheumatica

Women with polymyalgia rheumatica may have a small increase in the risk for mortality relative to the general population, but not during the first 20 years after diagnosis, according to research presented at the EULAR 2022 Congress in Copenhagen, Denmark.

Covid-19 vaccine concept

12-05-2022 | COVID-19 | News

Study identifies risk factors for RMD flares following COVID-19 vaccination

Research from the COVID-19 Global Rheumatology Alliance has identified a number of factors, including diagnosis and vaccine type, that are associated with flare risk following vaccination among people with rheumatic and musculoskeletal diseases.


12-04-2022 | Vasculitis | News

ALEVIATE trial: Alemtuzumab may warrant further investigation for refractory vasculitis

Findings from a phase 2b trial suggest that treatment with the anti-CD52 antibody alemtuzumab may be beneficial for some patients with primary systemic vasculitis and an inadequate response to conventional therapies.

Child in hospital bed hold hands with parent

24-03-2022 | Kawasaki disease | News

Network meta-analysis rates treatments for Kawasaki disease

Adding infliximab to standard therapy with high-dose intravenous immunoglobulin plus high-dose aspirin may decrease fever duration and prevent coronary artery lesions in children with Kawasaki disease, study findings indicate.

18-03-2022 | Polymyalgia rheumatica | News

Biomarkers may improve giant cell arteritis diagnosis

Measuring erythrocyte sedimentation rate, angiopoietin-2/-1 ratio, and matrix metalloprotease-3 levels may help discriminate patients with isolated polymyalgia rheumatica from those with concomitant giant cell arteritis, research suggests.

14-03-2022 | Giant cell arteritis | News

Phase 2 trial supports further investigation of JAK inhibitors for giant cell arteritis

Findings from a proof-of-concept trial provide preliminary evidence to suggest that the JAK inhibitor baricitinib is well tolerated and may have efficacy for the treatment of relapsing giant cell arteritis.

03-03-2022 | ANCA-associated vasculitis | News

Guidelines issued on plasma exchange, glucocorticoid dosing for ANCA-associated vasculitis

Clinical practice guidelines have been developed to advise on the role of plasma exchange and the optimal dose of glucocorticoids in people with antineutrophil cytoplasmic antibody-associated vasculitis.

Keep up with podcasts on this topic, available on